首页> 外文期刊>The Open Nuclear Medicine Journal >Radiopharmaceuticals for Molecular Imaging
【24h】

Radiopharmaceuticals for Molecular Imaging

机译:分子成像用放射性药物

获取原文
           

摘要

Radiopharmaceuticals for molecular imaging involve careful consideration of the following two factors:radionuclide selection and specificity to the molecular target. In selecting a radionuclide, the specific decay mode,physical half-life, chemical properties, and method of production must be considered. For proper design of aradiopharmaceutical which targets a specific biological or disease process, structural features, including the size, charge,solubility, lipophilicity, and specific activity of the radiolabeled molecules, must be considered. Other factors, such as therate of metabolism, plasma protein binding, and non-specific binding in non-target tissues, are also important inoptimizing the In Vivo behavior of radiolabeled molecules. There are several types of radiopharmaceuticals for molecularimaging that target a number of biochemical processes, such as blood flow or perfusion, metabolism, and specificreceptors. With a better understanding of the properties of radiopharmaceuticals, including chemical, physical, andbiological properties, radiopharmaceuticals can be properly used for molecular imaging of targets for biological or diseaseprocesses.
机译:用于分子成像的放射性药物需要仔细考虑以下两个因素:放射性核素的选择和对分子靶标的特异性。在选择放射性核素时,必须考虑特定的衰变模式,物理半衰期,化学性质和生产方法。为了正确设计针对特定生物学或疾病过程的放射性药物,必须考虑结构特征,包括大小,电荷,溶解度,亲脂性和放射性标记分子的比活性。其他因素,例如代谢速率,血浆蛋白结合和非靶组织中的非特异性结合,对于优化放射性标记分子的体内行为也很重要。针对分子成像的放射药物有几种类型,它们以许多生化过程为目标,例如血流或灌注,代谢和特异性受体。通过更好地了解放射性药物的性质,包括化学,物理和生物学性质,可以将放射性药物适当地用于生物学或疾病过程靶标的分子成像。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号